The division supports a clinical trial section, led by Khaled Ziada, MD, and clinical research manager Jennifer Isaacs, MS, CCRP. Phase I-IV drug and device clinical trials across a multitude of areas including structural heart disease, coronary artery disease, heart failure, and electrophysiology are currently in progress.
The strength of our clinical research efforts, particularly regarding innovative catheter-based approaches to heart and vascular disease, is unmatched. We lead the latest in cardiovascular treatment including renal denervation, left atrial pressure monitoring for heart failure, bioresorbable coronary stents and stem cell regenerative medicine. Historically, we have been a top enroller in multicenter trials investigating novel devices for PFO closure, left atrial pressure monitoring (to treat heart failure) and ASD closure, as well as novel drugs for treatment of ACS and the prevention of secondary coronary events.
Our strength and commitment to clinical trial research increases the accessibility of state-of-the-art treatments to patients across Kentucky that would otherwise not exist in this region of the country. The University of Kentucky Center for Clinical and Translational Science, which is supported by the National Institutes of Health, places the university in an elite group of 60 biomedical research institutions poised to solve the toughest challenges in medicine and surgery using innovative approaches.